Depression is frequently reported in epilepsy patients; however, mechanisms of co-morbidity between epilepsy and depression are poorly understood. An important mechanism of depression is disinhibition within the hypothalamo-pituitary-adrenocortical (HPA) axis. We examined the functional state of the HPA axis in a rat model of co-morbidity between temporal lobe epilepsy and depression. Epilepsy was accompanied by the interictal elevation of plasma corticosterone, and by the positively combined dexamethasone/corticotropin releasing hormone test. The extent of the HPA hyperactivity was independent of recurrent seizures, but positively correlated with the severity of depressive behavior. We suggest that the observed hyperactivity of the HPA axis may underlie co-morbidity between epilepsy and depression.
Introduction
Depression is one of the most common co-morbidities of epilepsy, including temporal lobe epilepsy (TLE), and has a high negative impact on the quality of life in epilepsy patients (Hermann et al., 2000; Kanner and Balabanov, 2002; Kondziella et al., 2007) . While psychosocial factors may contribute to depression in epilepsy, there is growing evidence that this condition has a neurobiological basis (Kanner, 2005; Kondziella et al., 2007) . Nevertheless, mechanisms that underlie depression in epilepsy are poorly understood, and its effective therapies are lacking.
Validation of animal models of co-morbidity between TLE and depression is instrumental for understanding mechanisms of this condition and for the development of its rational therapies. In the pursuit of such an animal model, we previously established that LiCl and pilocarpine status epilepticus (SE) in rats, along with chronic epilepsy, led to behavioral (despair and anhedonia) and biochemical (deficit of the raphe-hippocampal serotonergic transmission) hallmarks of depression (Mazarati et al., 2008) . However, since depression in epilepsy is a multifactorial disorder (Kanner, 2003; Kondziella et al., 2007) , the model validation process should include the identification of other contributing physiological, biochemical and endocrine factors.
One core feature of major depression is chronic stress (Chaouloff, 2000; El Yacoubi et al., 2003; Yu et al., 2008) which is manifested as the paucity of the negative feedback inhibition within the hypothalamo-pituitary-adrenocortical (HPA) axis: under conditions of chronic stress, cortisol fails to inhibit the production of corticotropin releasing hormone (CRH) and of adrenocorticotropic hormone (ACTH), thus resulting in a high sustained level of circulating cortisol (Herman and Cullinan, 1997) . The laboratory diagnosis of depression involves the dexamethasone (DEX)/CRH test, which is purposed to reveal the described HPA dysregulation: the test is considered positive, that is diagnostic of depression, if DEX fails to decrease the level of plasma cortisol, and if exogenously administered CRH leads to the exacerbated increase of the plasma stress hormone (Watson et al., 2006) .
While the described dysregulation of the HPA axis has been established in major depression, the role of this neuroendocrine impairment in depression associated with epilepsy has not been sufficiently examined. Nevertheless, several reports suggested that epilepsy may be indeed accompanied by chronic, interictal hyperactivity of the HPA axis evident as the increased content of plasma cortisol (Gallagher, 1987) and positive DEX/CRH test (Zobel et al., 2004) ; the latter study suggested that such chronic HPA dysfunction may be a factor contributing to depression in TLE. 
